Vera Therapeutics, Inc.
NASDAQ:VERA
37.51 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Vera Therapeutics, Inc. |
Symbool | VERA |
Munteenheid | USD |
Prijs | 37.51 |
Beurswaarde | 2,056,587,027 |
Dividendpercentage | 0% |
52-weken bereik | 9.24 - 50.78 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Marshall Fordyce M.D. |
Website | https://veratx.com |
An error occurred while fetching data.
Over Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)